Australia-based Invex Therapeutics (ASX:IXC) has received French regulatory approval to start its IIH EVOLVE Phase III clinical trial.
The trial will test the efficacy and safety of Presendin, a once-weekly treatment for neurological conditions caused by raised intracranial pressure.
The trial will include 240 patients with newly diagnosed Idiopathic Intracranial Hypertension (IIH), which has shown a 350% increase in incidence in the past decade.
Invex Therapeutics says it plans to open up to 40 clinical sites worldwide for the trial.